The top executive for global consulting firm McKinsey & Company is set to answer congressional questions Wednesday about the company’s work for U.S. health regulators even as it advised opioid drugmakers on how to boost sales of their prescription painkillers.
The hearing before a House committee is part of an ongoing investigation into McKinsey’s role in the U.S. opioid crisis that has been linked to over 500,000 overdose deaths from both prescription pain medications and illicit drugs like fentanyl.
Last year the consulting powerhouse agreed to pay $600 million to settle lawsuits over its work advising opioid makers, though it admitted no wrongdoing.
